Edward T. Richardson

1.4k citations

27 papers · 731 indexed · h-index 13

Co-authors: Supriya Shukla W. Henry Boom Niaz Banaei Pamela A. Wearsch Clifford V. Harding Sara M. Tolaney Elizabeth A. Mittendorf Eric P. Winer
Topics: Cancer Immunotherapy and Biomarkers (8 papers)Advanced Breast Cancer Therapies (6 papers)Tuberculosis Research and Epidemiology (6 papers)
Cited by: Infectious Diseases Oncology Immunology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaThe Journal of Immunology
Partner nations: United States Brazil Australia

In The Last Decade

Edward T. Richardson

27 papers receiving 721 citations

Peers

Countries citing papers authored by Edward T. Richardson

Since Specialization

Citations

This map shows the geographic impact of Edward T. Richardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward T. Richardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward T. Richardson more than expected).

Fields of papers citing papers by Edward T. Richardson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward T. Richardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward T. Richardson. The network helps show where Edward T. Richardson may publish in the future.

Co-authorship network of co-authors of Edward T. Richardson

This figure shows the co-authorship network connecting the top 25 collaborators of Edward T. Richardson. A scholar is included among the top collaborators of Edward T. Richardson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward T. Richardson. Edward T. Richardson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies 2024 ·Clinical Cancer Research ·Bojana Jovanović,S. Church,(unknown),Khrystyna North,Edward T. Richardson,(unknown),Victoria Attaya,(unknown),(unknown),Gregory J. Kirkner,Melissa E. Hughes,Nancy U. Lin,Elizabeth A. Mittendorf,Stuart J. Schnitt,Sara M. Tolaney,Shom Goel	3
2	Salivary Gland–like Tumors of the Breast 2023 ·Archives of Pathology & Laboratory Medicine ·Edward T. Richardson,Vickie Y. Jo,Stuart J. Schnitt	4
3	885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab 2023 ·SHILAP Revista de lepidopterología ·(unknown),Filipa Lynce,Xue Geng,Edward T. Richardson,(unknown),Mei Wei,Julie Collins,Paula R. Pohlmann,Arielle L. Heeke,(unknown),(unknown),(unknown),Jane Staunton,Stuart J. Schnitt,Joan S. Brugge,Hongkun Wang,Claudine Isaacs,Geoffrey I. Shapiro,Jennifer L. Guerriero	1
4	Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer 2023 ·Cancer Research ·Ana C. Garrido-Castro,(unknown),Edward T. Richardson,Allison Frangieh,(unknown),Melissa E. Hughes,(unknown),(unknown),Paolo Tarantino,Elizabeth A. Mittendorf,Sara M. Tolaney,Tari A. King,Eric P. Winer,Nancy U. Lin,Nikhil Wagle	1
5	NR4A3 Expression Is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift 2023 ·Modern Pathology ·Edward T. Richardson,Pier Selenica,Fresia Pareja,Paola Dal Cin,(unknown),Britta Weigelt,Jorge S. Reis‐Filho,Jason L. Hornick,Vickie Y. Jo,Stuart J. Schnitt	10
6	Abstract CT142: TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC) 2023 ·Cancer Research ·Filipa Lynce,(unknown),Xue Geng,Edward T. Richardson,(unknown),Mei Wei,Julie Collins,(unknown),Arielle L. Heeke,(unknown),(unknown),Jane Staunton,Stuart J. Schnitt,Joan S. Brugge,Hongkun Wang,Claudine Isaacs,Geoffrey I. Shapiro,Jennifer L. Guerriero	2
7	Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy 2022 ·Annals of Surgical Oncology ·Elizabeth A. Mittendorf,Olga Kantor,Anna Weiss,Edward T. Richardson,Ana C. Garrido-Castro,(unknown),Ian E. Krop,Nancy U. Lin,Eric P. Winer,Sara M. Tolaney,Tari A. King	7
8	Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy 2022 ·Current Problems in Surgery ·Faina Nakhlis,(unknown),Eva C. Gombos,(unknown),José Pablo Leone,Olga Kantor,Edward T. Richardson,Alice Y. Ho,(unknown),Nisha Ohri	1
9	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer 2022 ·Journal for ImmunoTherapy of Cancer ·Adrienne G. Waks,Tanya E. Keenan,Tianyu Li,Nabihah Tayob,Gerburg M. Wulf,Edward T. Richardson,Victoria Attaya,(unknown),Elizabeth A. Mittendorf,Beth Overmoyer,Eric P. Winer,Ian E. Krop,Judith Agudo,Eliezer M. Van Allen,Sara M. Tolaney	30
10	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study 2021 ·npj Breast Cancer ·Romualdo Barroso‐Sousa,Tanya E. Keenan,Tianyu Li,Nabihah Tayob,Lorenzo Trippa,Ricardo Pastorello,Edward T. Richardson,Deborah Dillon,Zohreh Amoozgar,Beth Overmoyer,Stuart J. Schnitt,Eric P. Winer,Elizabeth A. Mittendorf,Eliezer M. Van Allen,Dan G. Duda,Sara M. Tolaney	25
11	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer 2020 ·Clinical Breast Cancer ·Romualdo Barroso‐Sousa,Ian E. Krop,Lorenzo Trippa,(unknown),Tianyu Li,(unknown),Chelsea Andrews,Deborah Dillon,Edward T. Richardson,Ricardo Pastorello,Eric P. Winer,Elizabeth A. Mittendorf,Jennifer R. Bellon,Jonathan D. Schoenfeld,Sara M. Tolaney	57
12	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 2020 ·JAMA Oncology ·Sara M. Tolaney,Romualdo Barroso‐Sousa,Tanya E. Keenan,Tianyu Li,Lorenzo Trippa,Inês Vaz-Luís,Gerburg M. Wulf,Laura M. Spring,Natalie Sinclair,Chelsea Andrews,(unknown),Edward T. Richardson,Deborah Dillon,Nancy U. Lin,Beth Overmoyer,Ann H. Partridge,Eliezer M. Van Allen,Elizabeth A. Mittendorf,Eric P. Winer,Ian E. Krop	110
13	Retinoblastoma protein expression and its predictors in triple-negative breast cancer 2020 ·npj Breast Cancer ·Jaymin Patel,(unknown),Judy E. Garber,Vanda F. Torous,Edward T. Richardson,Miriam J. Haviland,Michele R. Hacker,Gordon J. Freeman,Tessa Nalven,Brian M. Alexander,Larissa J. Lee,Laura C. Collins,Stuart J. Schnitt,Nadine Tung	32
14	Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS 2019 ·Annals of Oncology ·Meghan Karuturi,Joanne L. Blum,John M. Wallmark,Steve McCune,Shailendra Lakhanpal,(unknown),(unknown),(unknown),Aditya Bardia,J.C. Cappelleri,Edward T. Richardson,(unknown),Debu Tripathy	4
15	Mycobacterium tuberculosis Lipoprotein and Lipoglycan Binding to Toll-Like Receptor 2 Correlates with Agonist Activity and Functional Outcomes 2018 ·Infection and Immunity ·Supriya Shukla,Edward T. Richardson,Michael G. Drage,W. Henry Boom,Clifford V. Harding	27
16	Mycobacterium tuberculosis Membrane Vesicles Inhibit T Cell Activation 2017 ·The Journal of Immunology ·Jaffre J. Athman,Obondo James Sande,(unknown),Scott M. Reba,Nancy Nagy,Pamela A. Wearsch,Edward T. Richardson,Roxana E. Rojas,W. Henry Boom,Supriya Shukla,Clifford V. Harding	80
17	ERK Signaling Is Essential for Macrophage Development 2015 ·PLoS ONE ·Edward T. Richardson,Supriya Shukla,Nancy Nagy,W. Henry Boom,Rose Beck,Lan Zhou,Gary E. Landreth,Clifford V. Harding	63
18	Mycobacterium tuberculosis Lipoprotein LprG Binds Lipoarabinomannan and Determines Its Cell Envelope Localization to Control Phagolysosomal Fusion 2014 ·PLoS Pathogens ·Supriya Shukla,Edward T. Richardson,Jaffre J. Athman,Libin Shi,Pamela A. Wearsch,David McDonald,Niaz Banaei,W. Henry Boom,Mary Jackson,Clifford V. Harding	62
19	Rapid Identification of Mycobacterium tuberculosis and Nontuberculous Mycobacteria by Multiplex, Real-Time PCR 2009 ·Journal of Clinical Microbiology ·Edward T. Richardson,(unknown),Niaz Banaei	75
20	My Thoughts: A Self-Evaluation Instrument. 1975 ·NASSP Bulletin ·Edward T. Richardson	1

About Edward T. Richardson

Edward T. Richardson is a scholar working on Oncology, Infectious Diseases and Cancer Research, having authored 27 papers that have together received 731 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Advanced Breast Cancer Therapies (6 papers) and Tuberculosis Research and Epidemiology (6 papers). The work is most often cited by research in Infectious Diseases (215 citations), Oncology (315 citations) and Immunology (212 citations). Edward T. Richardson has collaborated with scholars based in United States, Brazil and Australia. Frequent co-authors include Supriya Shukla, W. Henry Boom, Niaz Banaei, Pamela A. Wearsch, Clifford V. Harding, Sara M. Tolaney, Elizabeth A. Mittendorf, Eric P. Winer, Nancy Nagy and Tianyu Li. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact